{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:07:52Z","timestamp":1790809672664,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"European Union's Horizon 2020 research and innovation programme","doi-asserted-by":"publisher","award":["667787"],"award-info":[{"award-number":["667787"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SIRIC Curie","award":["INCa-DGOS-Inserm_12554"],"award-info":[{"award-number":["INCa-DGOS-Inserm_12554"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejca.2019.12.012","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T05:11:18Z","timestamp":1578546678000},"page":"93-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2\/XL\/W and MDM2 as a potential therapy in uveal melanoma"],"prefix":"10.1016","volume":"126","author":[{"given":"Didier","family":"Decaudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Frisch Dit Leitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Nemati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-9631","authenticated-orcid":false,"given":"Malcy","family":"Tarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Naguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Zerara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Marande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Vivet-Noguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ensar","family":"Halilovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart","family":"Jochemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Roman-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-1346","authenticated-orcid":false,"given":"Samar","family":"Alsafadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.12.012_bib1","doi-asserted-by":"crossref","DOI":"10.2147\/OPTH.S113623","article-title":"Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the surveillance, epidemiology, and end results database (1973\u20132012)","author":"Mahendraraj","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ejca.2019.12.012_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","article-title":"Uveal melanoma: a review of the literature","volume":"6","author":"Singh","year":"2018","journal-title":"Oncol Ther"},{"key":"10.1016\/j.ejca.2019.12.012_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11071019","article-title":"Emerging therapeutic opportunities based on current knowledge of uveal melanoma biology","author":"Vivet-Noguer","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2019.12.012_bib4","article-title":"The genetics of uveal melanoma: current insights","author":"Helgadottir","year":"2016","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.ejca.2019.12.012_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.12.012_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2019.12.012_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo pathway in organ size control, tissue homeostasis, and cancer","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2019.12.012_bib8","article-title":"The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma","author":"Wu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.12.012_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.01.009","article-title":"A Platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the hippo pathway through FAK","author":"Feng","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2019.12.012_bib10","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.24670","article-title":"Selumetinib-based therapy in uveal melanoma patient-derived xenografts","author":"Decaudin","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2019.12.012_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.molonc.2014.06.004","article-title":"Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target","author":"Amirouchene-Angelozzi","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2019.12.012_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","author":"Carvajal","year":"2014","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.ejca.2019.12.012_bib13","article-title":"Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma","author":"Piperno-Neumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.012_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: where are we now?","author":"Yang","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2019.12.012_bib15","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8054","article-title":"The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma","author":"Amirouchene-Angelozzi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2019.12.012_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(16)32672-7","article-title":"Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma","author":"Carita","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.12.012_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2013.418","article-title":"Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations","author":"Chen","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2019.12.012_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-11-3227","article-title":"Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner","author":"Khalili","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.12.012_bib19","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-13-0550","article-title":"The phosphoinositide 3-kinase \u03b1 selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ\/GNA11-Mutant uveal melanoma cells","author":"Musi","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2019.12.012_bib20","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23485","article-title":"Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma","author":"Heijkants","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2019.12.012_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-018-0041-y","article-title":"Targeting MDMX and PKC\u03b4 to improve current uveal melanoma therapeutic strategies","author":"Heijkants","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejca.2019.12.012_bib22","article-title":"ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2019.12.012_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-11-0415","article-title":"The Bcl-2\/Bcl-XL\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in\u00a0vitro and in\u00a0vivo","author":"Chen","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2019.12.012_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080836","article-title":"Targeting Bcl-2\/Bcl-X L induces antitumor activity in uveal melanoma patient-derived xenografts","author":"N\u00e9mati","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.12.012_bib25","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.6417","article-title":"Synergistic cooperation between ABT-263 and MEK1\/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells","author":"Airiau","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2019.12.012_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1620262114","article-title":"Resistance mechanisms to TP53-MDM2 inhibition identified by in\u00a0vivo piggyBac transposon mutagenesis screen in an Arf \u2212\/\u2212 mouse model","author":"Chapeau","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ejca.2019.12.012_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.01.009","article-title":"Novel synergistic combination of mitotic arrest and promotion of apoptosis for treatment of pancreatic adenocarcinoma","author":"Duan","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2019.12.012_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bjo.82.8.961","article-title":"Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma","author":"Coupland","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ejca.2019.12.012_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9440(10)64817-1","article-title":"Deregulation of the Rb and p53 pathways in uveal melanoma","author":"Brantley","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2019.12.012_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","author":"Gao","year":"2015","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2023.02.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T13:56:11Z","timestamp":1657029371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919308676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"alternative-id":["S0959804919308676"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.012","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2023.02.004","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2\/XL\/W and MDM2 as a potential therapy in uveal melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}